Tricha Shivas Promoted to Chief of Staff and Strategy at Foundation for Sarcoidosis Research
15 févr. 2024 06h23 HE
|
Foundation for Sarcoidosis Research
The Foundation for Sarcoidosis Research (FSR) proudly announces the promotion of Tricha Shivas to Chief of Staff and Strategy.
The Foundation for Sarcoidosis Research (FSR) awards $100,000 in support of cardiac sarcoidosis
18 déc. 2023 15h41 HE
|
Foundation for Sarcoidosis Research
The Foundation for Sarcoidosis Research (FSR) awards $100,000 in support of cardiac sarcoidosis.
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
09 nov. 2023 11h00 HE
|
Novartis Pharma AG
In pivotal Phase III trials, remibrutinib – a highly selective, oral Bruton’s tyrosine kinase inhibitor – demonstrated clinically meaningful and statistically significant reduction in urticaria...
Foundation for Sarcoidosis Research Announces 3 New Members to the 40 Member FSR Global Sarcoidosis Clinic Alliance through its FSR-GSCA Capacity Building Grants
01 nov. 2023 11h26 HE
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research announces three clinics that have been selected as members of FSR Global Sarcoidosis Clinic Alliance
FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
31 oct. 2023 16h50 HE
|
Novartis Pharma AG
FDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 21 As the only IL-17A inhibitor...
Foundation for Sarcoidosis Research announces largest Global Sarcoidosis Virtual Summit – Find Your Community, Find Your Life
26 sept. 2023 09h15 HE
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research to Host Largest Virtual Sarcoidosis Educational Event of the Year
Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria
09 août 2023 01h15 HE
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR The Phase III REMIX-1 and REMIX-2 studies met all primary and secondary endpoints, showing rapid, clinically meaningful improvements across...
Global Pet Insurance Market Foreseen to Garner $28,377.8 Million, Growing at 15.3% CAGR in the 2021–2028 Timeframe [235-Pages] | Announced by Research Dive
20 avr. 2023 10h25 HE
|
Research Dive
New York, USA, April 20, 2023 (GLOBE NEWSWIRE) -- Research Dive has published a new report on the global pet insurance market. According to the report, the global market is projected to surpass...
With Expanded Outdoor Features, Lifestyle Healing Institute Integrates Traditional and Holistic Medicine
29 août 2022 08h04 HE
|
Lifestyle Healing Institute
NAPLES, Fla., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Lifestyle Healing Institute, a center for complementary and alternative medicine, treats illnesses with data-driven approaches delivered by a medical...
Growth: Significant Rise in the Adoption of Pets Across the Globe to Propel the Growth of the Global Pet Insurance Market [235-Pages] | Reveals by Research Dive
21 mars 2022 09h05 HE
|
Research Dive
New York, USA, March 21, 2022 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global pet insurance market is expected to generate a revenue of $28,377.8 million by 2028,...